Ofranergene obadenovec
Gene therapyexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00559117)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor receptor R1INHIBITOR
TNFRSF1A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707381 ↗
Also known as
- vb-111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04166383 | Phase 2 | Dec 6, 2019 | National Cancer Institute (NCI) |
| NCT03398655 | Phase 3 | Dec 19, 2017 | GOG Foundation, Inc., VBL |
| NCT02511405 | Phase 3 | Aug 1, 2015 | VBL |
| NCT01229865 | Phase 2 | Dec 1, 2010 | VBL |
| NCT01260506 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | VBL |
| NCT00559117 | Phase 1 | Nov 1, 2007 | University of Rochester, University of Texas, San Antonio, VBL |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VBL | For profit | 5 | 5 | 3 | 2007 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2019 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2007 |
5 organizations
Page 1 / 1